Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of RC148 alone and in combination for advanced unresectable or metastatic solid tumors
CTR20232413Phase 2Active
- Sponsor
- RemeGen
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RC148 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), Cervical Cancer (CC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by RemeGen. Started Sep 2023; status: active.
02
Drugs
RC148
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)Cervical Cancer (CC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20232413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232413.